Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating) Director Andrew A. F. Hack bought 80,759 shares of the stock in a transaction that occurred on Tuesday, May 31st. The stock was purchased at an average price of $3.28 per share, for a total transaction of $264,889.52. Following the completion of the purchase, the director now directly owns 8,648,913 shares in the company, valued at approximately $28,368,434.64. The transaction was disclosed in a filing with the SEC, which is available through this link.
NASDAQ MRSN traded up $0.01 during midday trading on Thursday, hitting $3.22. The company had a trading volume of 726,636 shares, compared to its average volume of 1,677,655. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 0.18. The stock has a market cap of $312.31 million, a price-to-earnings ratio of -1.29 and a beta of 2.38. The firm has a fifty day simple moving average of $3.75 and a two-hundred day simple moving average of $4.83. Mersana Therapeutics, Inc. has a fifty-two week low of $2.68 and a fifty-two week high of $15.34.
Mersana Therapeutics (NASDAQ:MRSN – Get Rating) last posted its quarterly earnings results on Monday, May 9th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.28). Mersana Therapeutics had a negative return on equity of 119.10% and a negative net margin of 8,826.73%. During the same quarter last year, the business earned ($0.50) earnings per share. As a group, equities analysts predict that Mersana Therapeutics, Inc. will post -2.13 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its position in Mersana Therapeutics by 2.0% in the 1st quarter. BlackRock Inc. now owns 7,626,196 shares of the company’s stock worth $30,427,000 after purchasing an additional 146,967 shares during the last quarter. Sarissa Capital Management LP boosted its position in shares of Mersana Therapeutics by 7.3% during the 3rd quarter. Sarissa Capital Management LP now owns 4,299,297 shares of the company’s stock valued at $40,542,000 after acquiring an additional 293,697 shares in the last quarter. State Street Corp boosted its position in shares of Mersana Therapeutics by 3.2% during the 4th quarter. State Street Corp now owns 4,220,557 shares of the company’s stock valued at $26,252,000 after acquiring an additional 130,361 shares in the last quarter. Rock Springs Capital Management LP boosted its position in shares of Mersana Therapeutics by 15.6% during the 1st quarter. Rock Springs Capital Management LP now owns 3,755,820 shares of the company’s stock valued at $14,986,000 after acquiring an additional 506,870 shares in the last quarter. Finally, Artal Group S.A. boosted its position in shares of Mersana Therapeutics by 83.3% during the 1st quarter. Artal Group S.A. now owns 2,200,000 shares of the company’s stock valued at $8,778,000 after acquiring an additional 1,000,000 shares in the last quarter. Institutional investors own 92.74% of the company’s stock.
MRSN has been the topic of a number of research analyst reports. Robert W. Baird lowered their target price on shares of Mersana Therapeutics from $23.00 to $18.00 in a research note on Tuesday, May 10th. Zacks Investment Research lowered shares of Mersana Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 11th. HC Wainwright lowered their target price on shares of Mersana Therapeutics from $24.00 to $19.00 in a research note on Monday, May 9th. Finally, SVB Leerink lowered their target price on shares of Mersana Therapeutics from $25.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, February 18th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $17.80.
Mersana Therapeutics Company Profile (Get Rating)
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.
Receive News & Ratings for Mersana Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Mersana Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.